<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318470</url>
  </required_header>
  <id_info>
    <org_study_id>10-00505-JD</org_study_id>
    <nct_id>NCT04318470</nct_id>
  </id_info>
  <brief_title>Identification of Microbial DNA in Maternal Plasma After PPROM</brief_title>
  <official_title>Using Metagenomic Next-generation Sequencing to Identify Microbial DNA in Maternal Plasma in Cases of Preterm Premature Rupture of Membranes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of metagenomic next generation sequencing in identifying
      microbial DNA in plasma samples of patients with preterm premature rupture of membranes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although preterm premature rupture of membranes (PPROM) occurs in only 3% of pregnancies, it
      accounts for 30% of preterm births (PTB) and is associated with serious maternal and neonatal
      morbidity. An important factor in the underlying pathophysiology of PPROM and subsequent PTB
      is subclinical infection, which promotes a cascade of events that contribute to synthesis of
      prostaglandins, release of proinflammatory cytokines, infiltration of neutrophils, and
      activation of metalloproteases. Over time, enhanced activity of these infectious and
      inflammatory pathways contributes to the development of spontaneous labor and/or overt
      intraamniotic infection (IAI). Unfortunately, the majority of patients with PPROM do not
      manifest signs and symptoms of infection that are detectable by clinical examination,
      laboratory evaluation, and traditional microdiagnostic tests, and attempting to predict
      length of latency period and/or timing of delivery remains a clinical challenge. We propose
      the use of metagenomic next-generation sequencing (mNGS) to identify microbial DNA in
      maternal plasma following PPROM. We hypothesize that the presence and abundance of microbial
      DNA is associated with a shorter latency period and that an increase in the abundance of
      microbial DNA precedes delivery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Length of latency</measure>
    <time_frame>From study enrollment to date of delivery, up to 24 weeks</time_frame>
    <description>Time between PPROM and delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal infectious morbidity</measure>
    <time_frame>From study enrollment to date of delivery, up to 30 weeks</time_frame>
    <description>Composite of fever, intrauterine infection, sepsis, postpartum endometritis, surgical site infection, and administration of antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal infectious morbidity</measure>
    <time_frame>From neonatal birth to neonatal hospital discharge, up to 1 year</time_frame>
    <description>Composite of fever, sepsis, administration of antibiotics, and need for blood/urine/cerebrospinal fluid (CSF) cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological signs of infection</measure>
    <time_frame>At time of placental delivery</time_frame>
    <description>Histopathological signs of infection on routine post-delivery examination of placenta, membranes, and umbilical cord</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal demise</measure>
    <time_frame>From study enrollment to 28 days of life</time_frame>
    <description>Composite of intrauterine fetal demise and neonatal demise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to neonatal intensive care unit (NICU)</measure>
    <time_frame>From neonatal birth to neonatal hospital discharge, up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NICU length of stay</measure>
    <time_frame>From neonatal birth to neonatal hospital discharge, up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal need for supplemental oxygen</measure>
    <time_frame>From neonatal birth to neonatal hospital discharge, up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory distress syndrome</measure>
    <time_frame>From neonatal birth to neonatal hospital discharge, up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing enterocolitis</measure>
    <time_frame>From neonatal birth to neonatal hospital discharge, up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraventricular hemorrhage</measure>
    <time_frame>From neonatal birth to neonatal hospital discharge, up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Preterm Rupture of Membranes</condition>
  <arm_group>
    <arm_group_label>PPROM</arm_group_label>
    <description>Preterm premature rupture of membranes between 16 0/7 and 33 6/7 weeks gestation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Gestational-age-matched controls without preterm premature rupture of membranes or other pregnancy complications</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>mNGS</intervention_name>
    <description>Metagenomic next generation sequencing for microbial DNA</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>PPROM</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant patients with preterm premature rupture of membranes and gestational-age-matched
        controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For PPROM group, preterm premature rupture of membranes between 16 0/7 and 33 6/7
             weeks of gestation

          -  For control group, healthy pregnancy with no evidence of preterm premature rupture of
             membranes or other major complications

        Exclusion Criteria:

          -  Maternal age &lt; 18 years

          -  Major fetal congenital malformation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasim C Sobhani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nasim C Sobhani, MD</last_name>
    <phone>(415) 502-3231</phone>
    <email>Nasim.Sobhani@UCSF.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasim C Sobhani, MD</last_name>
      <phone>415-502-3231</phone>
      <email>Nasim.Sobhani@UCSF.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

